Van ECK Associates Corp Buys 3,066 Shares of Repligen Co. (NASDAQ:RGEN)

Van ECK Associates Corp boosted its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 7.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,226 shares of the biotechnology company's stock after purchasing an additional 3,066 shares during the period. Van ECK Associates Corp owned about 0.08% of Repligen worth $6,078,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Champlain Investment Partners LLC grew its position in shares of Repligen by 149.0% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company's stock valued at $211,464,000 after acquiring an additional 850,345 shares during the period. Conestoga Capital Advisors LLC lifted its stake in Repligen by 0.7% in the 4th quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company's stock valued at $136,395,000 after purchasing an additional 6,872 shares during the last quarter. Thrivent Financial for Lutherans grew its holdings in Repligen by 6.1% during the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company's stock worth $95,037,000 after purchasing an additional 36,773 shares during the period. DF Dent & Co. Inc. increased its position in Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company's stock worth $87,852,000 after buying an additional 139,615 shares during the last quarter. Finally, New York State Common Retirement Fund increased its position in Repligen by 14.4% during the third quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company's stock worth $84,387,000 after buying an additional 71,274 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Repligen Price Performance

Repligen stock traded down $3.68 during trading hours on Friday, reaching $158.99. 795,356 shares of the stock were exchanged, compared to its average volume of 609,046. The stock has a 50 day moving average of $155.22 and a two-hundred day moving average of $148.79. The company has a market cap of $8.91 billion, a P/E ratio of -429.69, a price-to-earnings-growth ratio of 4.23 and a beta of 0.99. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $203.13.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Equities analysts expect that Repligen Co. will post 1.54 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on RGEN. Canaccord Genuity Group lifted their target price on Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a research note on Friday. HC Wainwright reaffirmed a "buy" rating and set a $180.00 price target on shares of Repligen in a report on Friday. Royal Bank of Canada upped their price objective on shares of Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a report on Friday. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research note on Friday, January 3rd. Finally, JPMorgan Chase & Co. upped their target price on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $183.36.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.